GLPG vs. AMRX, EVO, GPCR, AGIO, RNA, NAMS, RCKT, SNDX, CPRX, and SDGR
Should you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Amneal Pharmaceuticals (AMRX), Evotec (EVO), Structure Therapeutics (GPCR), Agios Pharmaceuticals (AGIO), Avidity Biosciences (RNA), NewAmsterdam Pharma (NAMS), Rocket Pharmaceuticals (RCKT), Syndax Pharmaceuticals (SNDX), Catalyst Pharmaceuticals (CPRX), and Schrödinger (SDGR). These companies are all part of the "pharmaceutical preparations" industry.
Galapagos (NASDAQ:GLPG) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, community ranking, valuation, dividends and media sentiment.
Galapagos has higher earnings, but lower revenue than Amneal Pharmaceuticals. Galapagos is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Amneal Pharmaceuticals had 19 more articles in the media than Galapagos. MarketBeat recorded 25 mentions for Amneal Pharmaceuticals and 6 mentions for Galapagos. Amneal Pharmaceuticals' average media sentiment score of 0.33 beat Galapagos' score of 0.13 indicating that Amneal Pharmaceuticals is being referred to more favorably in the news media.
32.5% of Galapagos shares are owned by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 2.9% of Galapagos shares are owned by insiders. Comparatively, 17.5% of Amneal Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Galapagos has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.
Galapagos received 457 more outperform votes than Amneal Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Amneal Pharmaceuticals an outperform vote while only 64.54% of users gave Galapagos an outperform vote.
Galapagos presently has a consensus price target of $34.50, indicating a potential upside of 19.92%. Amneal Pharmaceuticals has a consensus price target of $8.25, indicating a potential upside of 27.51%. Given Amneal Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Amneal Pharmaceuticals is more favorable than Galapagos.
Amneal Pharmaceuticals has a net margin of -6.76% compared to Galapagos' net margin of -26.25%. Amneal Pharmaceuticals' return on equity of 234.06% beat Galapagos' return on equity.
Summary
Amneal Pharmaceuticals beats Galapagos on 14 of the 18 factors compared between the two stocks.
Get Galapagos News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galapagos Competitors List
Related Companies and Tools
